Company is developing dual agonist and tri-agonist drugs that target GLP-1 alongside other metabolic hormones like GIP and glucagon.
With Novo Nordisk continuing to break sales records with its obesity and diabetes drugs Wegovy and Ozempic, investment in weight loss drug development shows no signs of slowing up. Boston-based biotech Kailera Therapeutics is the latest player to enter the arena, emerging with a whopping $400 million Series A funding round to advance a portfolio of therapies for “obesity and related conditions.”
Kailera is developing both injectable and oral treatments that have already shown promise in clinical-stage trials. The company’s pipeline has been exclusively licensed from Chinese pharma giant Jiangsu Hengrui Pharmaceuticals for global development and commercialization outside of China.
While Wegovy and Ozempic are agonists of the key GLP-1 hormone that is involved in the control of blood sugar level by enhancing insulin secretion, Kailera is also developing “dual agonist” and “tri-agonist” drugs that target both GLP-1 and other key metabolic hormones, including GIP and glucagon. With increasing evidence appearing to show that weight loss drugs are having a wider impact on human health – potentially even on aging itself – there will be a continued interest in whether the next generation of these drugs continue to demonstrate such benefits.
The company’s most advanced therapy is KAI-9531, an injectable GLP-1/GIP receptor dual agonist (similar to Eli Lilly’s Zepbound and Mounjaro) that has already shown positive results in Phase 2 trials for obesity and type 2 diabetes in China. Kailera’s pipeline also includes KAI-7535, a clinical-stage oral GLP-1 receptor agonist, KAI-9531 in oral tablet form, and KAI-4729, a tri-agonist that targets glucagon alongside GLP-1 and GIP.
The company is headed by CEO Ron Renaud, a former exec at companies including Translate Bio, Idenix Pharmaceuticals, and Cerevel Therapeutics, which was acquired by AbbVie in 2024.
“In this period of rapid innovation in the metabolic space, I believe that Kailera is poised to make an impact beyond the current market leaders,” said Renaud. “We have an incredible opportunity to develop next-generation treatments for chronic weight management, helping people reclaim their health and live their lives to the fullest.”
The financing was co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with Lyra Capital also participating.
